Q1 2026 Earnings Show Revenue Growth Amidst Profitability Decline and EU Regulatory Setback for DAYBUE
ACAD sits 45% above its 52-week low of $14.45 on elevated volume (1.9× avg).
Summary
Acadia Pharmaceuticals reported increased Q1 2026 revenue but a sharp drop in net income due to higher operating expenses, alongside a confirmed negative EU regulatory opinion for its key drug DAYBUE, though liquidity remains strong.
Key Events · Earnings and Guidance · ACAD
-
Q1 Revenue Growth
Net product sales increased to $268.1 million in Q1 2026, up from $244.3 million in Q1 2025, driven by growth in both NUPLAZID and DAYBUE sales.
-
Significant Profitability Decline
Net income decreased sharply to $3.6 million in Q1 2026, down from $18.9 million in Q1 2025, primarily due to increased operating expenses.
-
Increased Operating Expenses
Selling, General and Administrative (SG&A) expenses rose significantly to $171.0 million in Q1 2026 from $126.4 million in Q1 2025, reflecting higher commercialization investments.
-
EU Regulatory Setback for DAYBUE
The EMA's CHMP issued a negative opinion on the marketing authorization application for trofinetide (DAYBUE) in the EU, confirming a prior disclosure, though a re-examination has been requested.
Analysis · ACAD · Life Sciences
Acadia Pharmaceuticals reported mixed first-quarter results, with solid revenue growth driven by its key products, NUPLAZID and DAYBUE. However, this was overshadowed by a significant decline in net income, primarily due to a substantial increase in selling, general, and administrative expenses as the company invests heavily in commercialization. A major concern is the confirmed negative opinion from the European Medicines Agency's (EMA) CHMP regarding the marketing authorization for trofinetide (DAYBUE) in the EU, which represents a significant setback for international expansion, despite a re-examination request. The company maintains a strong liquidity position, which is crucial for funding its active pipeline development and ongoing commercial efforts. Investors should monitor the outcome of the EU re-examination and the company's ability to improve profitability while continuing pipeline advancements.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACAD was trading at $21.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $14.45 to $28.35. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.